The Technical Analyst
Select Language :
Purple Biotech Ltd. [PPBT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Purple Biotech Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Purple Biotech Ltd. is listed at the  Exchange

8.06% $0.670

America/New_York / 28 mar 2024 @ 16:00


Purple Biotech Ltd.: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 17.38 mill
EPS: -0.900
P/E: -0.740
Earnings Date: May 09, 2024
SharesOutstanding: 25.94 mill
Avg Daily Volume: 0.101 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.740 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.13x
Company: PE -0.740 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.574
(-14.29%) $-0.0957
Date: 2024-03-29
Expected Trading Range (DAY)

$ 0.583 - 0.757

( +/- 12.99%)
ATR Model: 14 days

Forecast: 16:00 - $0.670

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $0.670
Forecast 2: 16:00 - $0.670
Forecast 3: 16:00 - $0.670
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.670 (8.06% )
Volume 0.0924 mill
Avg. Vol. 0.101 mill
% of Avg. Vol 91.79 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Purple Biotech Ltd.

Last 12 Months

Last 12 months chart data with high, low, open and close for Purple Biotech Ltd.

RSI

Intraday RSI14 chart for Purple Biotech Ltd.

Last 10 Buy & Sell Signals For PPBT

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Purple Biotech Ltd.

PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Last 10 Buy Signals

Date Signal @
STORJUSDMar 29 - 06:07$0.802
YAKUSDMar 29 - 06:04829.07
TBTCUSDMar 29 - 06:0569 757
POLSUSDMar 29 - 06:03$1.200
OCEANUSDMar 29 - 05:581.402
GRSUSDMar 29 - 05:53$0.730
KP3RUSDMar 29 - 05:5397.58
GTCUSDMar 29 - 05:512.21
YGGUSDMar 29 - 05:49$1.183
USDCUSDMar 29 - 05:48$1.000

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.